Long-term results of the Tata Memorial trial initially indicating weekly cisplatin dosed at 30 mg/m2 does not pass muster when compared to the more toxic q3-weekly at 100mg/m2 confirm a detriment in 5-year local control with the weekly (48%) versus q3-weekly (59%) regimen. | Noronha, Int J Radiat Oncol Biol Phys 2024
